Nedosiran (sodium)
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH) . Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD) . Nedosiran sodium is a GalNAc-dsRNA conjugate[1][2][3].
Product Specifications
CAS Number
2247026-22-6
Product Name Alternative
DCR-PHXC (sodium)
UNSPSC
12352208
Target
Lactate Dehydrogenase; Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/nedosiran-sodium.html
Purity
92.35
Solubility
H2O : 100 mg/mL (ultrasonic)
Smiles
[Nedosiran(sodium)]
Molecular Formula
C662H865F19N231O413P57S6.xNa
Molecular Weight
20985 (free acid)
References & Citations
[1]Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149.|[2]Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6 (4) :1088-1098.|[3]Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2021 May 22.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Oligonucleotides
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
